Cancer Clinical Trials Information Platform in Hong Kong


  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials


Cancer Site


*in alphabetical order (Last updated on 07/07/2025)


Others

Institution Study Title  
HKU Biliary Tract Canccer & Solid Tumors other than squamous/adenocarcinoma NSCLC, BTC, HNSCC, pancreatic adenocarcinoma, primary brain tumor and lymphoma
( UW 22-014 CTC2265) A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors		 Click for Details
HKU Rectal Adenocarcinoma
(UW21-577)_A randomized study of neoadjuvant chemoradiotherapy with or without intensification with the FOLFOXIRI chemo-regimen for high-risk locally advanced rectal cancer 		Click for Details
CUHK Biliary Tract Cancer
(BTC005)
A Phase III Randomized, Double-Blind, Placebo-Controlled,Multi-Regional, International Study of Durvalumab in Combination withGemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plusCisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1) 		Click for Details
CUHK Biliary Tract Cancer
(BTC008)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)		 Click for Details
CUHK Biliary Tract Cancer
(BTC009)
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements		 Click for Details
CUHK Cancer Pain
(SYM012)A pilot randomized open-labeled study comparing a structured titration method of immediate- and sustained-release oxycodone versus titration of investigators’ choice inadvanced cancer patients in Hong Kong 		Click for Details
CUHK Tenosynovial Giant Cell Tumor
(TGC001) A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION) 		Click for Details
CUHK (GIS001) (Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors Click for Details


For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.